Biotech News
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March.
| Leerink Partners Global Healthcare Conference | ||
|---|---|---|
| Date: | March 10, 2026 | |
| Time: | 1:00pm Eastern | |
| Format: | Fireside Chat | |
| Webcast: | Link to webcast | |
| Citizens Life Sciences Conference | ||
| Date: | March 11, 2026 | |
| Time: | 9:35am Eastern | |
| Format: | Fireside Chat | |
| Webcast: | Link to webcast | |
| Barclays 28 th Annual Global Healthcare Conference | ||
| Date: | March 12, 2026 | |
| Format: | One-on-one investor meetings |
About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath ® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN ® (minocycline) for Injection, REZZAYO ® (rezafungin for injection), VABOMERE ® (meropenem and vaborbactam), ORBACTIV ™ (oritavancin), BAXDELA ® (delafloxacin), and KIMYRSA ® (oritavancin), as well as TOPROL-XL ® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com .
Investor Contact: Dan Ferry Managing Director LifeSci Advisors [email protected] (617) 430-7576